{"id":38507,"date":"2026-05-06T10:59:00","date_gmt":"2026-05-06T14:59:00","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=38507"},"modified":"2026-04-27T14:47:51","modified_gmt":"2026-04-27T18:47:51","slug":"biosimilar-patent-wars-reveal-exactly-where-biopharma-talent-is-heading-next","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/biosimilar-patent-wars-reveal-exactly-where-biopharma-talent-is-heading-next\/","title":{"rendered":"Biosimilar Patent Wars Reveal Exactly Where Biopharma Talent Is Heading Next"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

How litigation patterns, settlement timelines, and competitive pressure in biologics are rewriting the industry’s talent map \u2014 and what that means for executives, IP professionals, and recruiters who want to get ahead of it.<\/em><\/p>\n\n\n\n

\n\n\n\n

Part I: Reading the Patent Map as a Talent Map<\/strong><\/h2>\n\n\n\n

There is a reliable pattern in biopharma that almost nobody talks about explicitly: where the lawyers go, the scientists follow. And where both converge, the next generation of commercially important companies gets built.<\/p>\n\n\n\n

Patent litigation in biologics is expensive, slow, and deeply technical. A single BPCIA case \u2014 the framework governing biosimilar patent disputes in the U.S. \u2014 can generate more than $10 million in legal costs, take three to five years to resolve, and require expert witnesses across at least three scientific disciplines. Companies do not commit those resources arbitrarily. When a company files or defends a BPCIA lawsuit, it is declaring, in legal language, exactly what molecule it considers worth fighting over. When a biosimilar developer settles, the settlement date it negotiates is essentially a public forecast of when it expects to enter a market with a commercial team, a regulatory dossier, a manufacturing supply chain, and enough personnel to run all three simultaneously.<\/p>\n\n\n\n

That settlement date is also, indirectly, a talent acquisition timeline. A company that settles for a Q4 2026 launch date needs its commercial infrastructure fully staffed by at least Q2 2026. It needs its regulatory lead in place 12 to 18 months before that, its CMC (chemistry, manufacturing, and controls) team locked in during development, and its IP counsel embedded even earlier to manage the litigation that produced the settlement. None of that happens without active, competitive recruiting.<\/p>\n\n\n\n

Across 2024 and 2025, an unusual number of major biologic patent disputes settled in clusters, and those clusters represent something close to a public announcement of which companies are hiring aggressively. The Eylea (aflibercept) litigation resolved into a series of overlapping settlements involving Amgen, Biocon, Sandoz, Alvotech, Samsung Bioepis, and Formycon, each securing a U.S. entry date in Q4 2026 or early 2027. Ustekinumab biosimilars reached the U.S. market in early 2025. Natalizumab biosimilars are heading to trial. And Keytruda’s (pembrolizumab) primary U.S. patent, protecting a drug with $29 billion in 2024 sales, expires in 2028, with at least seven companies already in development programs targeting it.<\/p>\n\n\n\n

Each of those data points maps to a talent need. And for anyone tracking where the industry’s best scientists, lawyers, regulatory executives, and commercial leads are going next, the patent register is among the most reliable leading indicators available.<\/p>\n\n\n\n

This article treats litigation data and biosimilar pipeline intelligence as predictive instruments for talent migration. It draws on active patent disputes, settlement timelines, regulatory changes, and market growth projections to identify which companies are building, which are consolidating, and which are quietly hollowing out their biosimilar functions \u2014 and what each of those postures means for the people who work in them.<\/p>\n\n\n\n

Databases like DrugPatentWatch provide the underlying patent-level data that make this kind of analysis possible, tracking expiry dates, secondary patent portfolios, and litigation activity across the industry. What follows is an attempt to translate that data into a talent forecast.<\/p>\n\n\n\n

\n\n\n\n

Part II: The BPCIA Battlefield \u2014 Where the Industry’s Best IP Talent Is Concentrated<\/strong><\/h2>\n\n\n\n

The Patent Dance and Its Professional Ecosystem<\/strong><\/h3>\n\n\n\n

The Biologics Price Competition and Innovation Act of 2009 created a legal framework that is, by design, labor-intensive. The so-called ‘patent dance’ \u2014 the structured pre-litigation exchange of information between biosimilar applicants and reference product sponsors \u2014 requires both sides to deploy specialized teams that barely existed a decade ago. A biosimilar applicant must assemble a list of potentially infringed patents, generate infringement and invalidity positions on each one, and then negotiate which patents enter the first round of litigation, all before a single complaint is filed in court. <blockquote> ‘Patent thickets and litigation abuses hinder all biosimilars. US litigation involves a staggering number of asserted patents \u2014 11 to 65 per product \u2014 far exceeding other countries,’ according to a July 2025 report from the Association for Accessible Medicines. [1] <\/blockquote><\/p>\n\n\n\n

That 11-to-65-patent range per product is not an abstraction. It describes the reality facing any scientific or legal professional who works on a biosimilar program in the U.S. today. Humira’s 132-patent thicket, which AbbVie assembled across two decades and defended successfully through antitrust litigation all the way to the Seventh Circuit, set the template. [2] Companies that replicated it \u2014 more modestly but persistently \u2014 have delayed biosimilar competition by years and, in the process, created sustained demand for two overlapping talent categories: the innovator-side IP attorneys who build and defend these portfolios, and the biosimilar-side scientists and litigators who challenge them.<\/p>\n\n\n\n

Both groups are now in motion.<\/p>\n\n\n\n

Who Builds Patent Thickets \u2014 and Where Those People Go<\/strong><\/h3>\n\n\n\n

On the innovator side, AbbVie’s strategy for Humira is the canonical example of how concentrated investment in IP prosecution talent generates long-term market protection. AbbVie filed hundreds of secondary patent submissions \u2014 almost half of them after 2014, just two years before the core patent’s expiration. [3] Those patents covered manufacturing processes, formulation changes, concentration variants, and device designs. The Seventh Circuit, reviewing the resulting antitrust complaint, asked a pointed question: ‘If AbbVie made 132 inventions, why can’t it hold 132 patents?’ [4] The court found AbbVie’s ‘batting average’ of 0.534 before the USPTO \u2014 a patent grant rate \u2014 ‘stellar in patent practice and unheard-of in baseball.’ [4]<\/p>\n\n\n\n

That batting average reflects sustained, specialist investment in patent prosecution talent. AbbVie did not build a thicket of 132 patents by accident or by outsourcing to generalist IP firms. It built a deep internal function of patent attorneys, scientific advisors, and IP strategists dedicated to Humira’s protection, supplemented by outside counsel from firms like Latham & Watkins, which continues to advise major innovator companies on BPCIA enforcement today.<\/p>\n\n\n\n

When blockbuster biologics approach their patent cliffs, what happens to that internal IP talent? Some stay with the company and pivot to lifecycle management \u2014 developing the subcutaneous formulation, the new concentration, the device patent that extends exclusivity on the follow-on product. Merck’s strategy for Keytruda illustrates this exactly: it filed 237 related patents around the original molecule, launched Keytruda Qlex (a subcutaneous formulation) in September 2025, and is pursuing a patent on that formulation estimated to expire around 2039. [5, 6] That subcutaneous program requires its own CMC team, its own formulation scientists, and its own IP counsel \u2014 all of whom are working on a product designed to complicate the lives of the pembrolizumab biosimilar developers currently in Phase 1 trials at Samsung Bioepis, Sandoz, Celltrion, Bio-Thera, and Amgen. [7]<\/p>\n\n\n\n

The talent implication is direct: Merck’s most experienced Keytruda IP professionals are not looking for new jobs right now. They are fully deployed on lifecycle defense. The professionals who will move are those at smaller innovator programs whose patent strategies have either run their course or been overturned by the courts.<\/p>\n\n\n\n

Where Biosimilar-Side IP Talent Goes When a Case Resolves<\/strong><\/h3>\n\n\n\n

On the biosimilar side, litigation resolution is a trigger for internal reorganization. When a company secures a settlement and a licensed entry date, the patent attorneys and scientific experts who drove the case either rotate to the next program or \u2014 if the company does not have another major litigation in the pipeline \u2014 become available to the market.<\/p>\n\n\n\n

The Eylea litigation produced a textbook example of this dynamic. Regeneron filed BPCIA complaints against at least six biosimilar developers: Celltrion, Samsung Bioepis, Amgen, Biocon (formerly Mylan in the litigation), Formycon\/Sandoz, and additional respondents. [8] The cases varied substantially in how they progressed through the patent dance. Amgen launched its biosimilar Pavblu at risk in October 2024 after the Federal Circuit denied Regeneron’s injunction application. [9] Sandoz settled in September 2025, securing a Q4 2026 U.S. entry date for Enzeevu, after Regeneron had asserted 46 patents against it. [10] Biocon settled in April 2025, clearing a second-half 2026 launch for Yesafili. [11] Samsung Bioepis reached a separate agreement allowing OPUVIZ to launch in January 2027. [12]<\/p>\n\n\n\n

Each settlement represents roughly 12 to 36 months of intensive IP litigation work that is now concluding. The attorneys, patent analysts, and scientific experts who staffed those cases are \u2014 depending on their employer’s next program \u2014 either immediately redeployed or available. For the companies that won entry dates, the transition is from litigation mode to commercial preparation mode: different skills, different people, different hires.<\/p>\n\n\n\n

\n\n\n\n

Part III: The Humira Aftermath \u2014 What the Adalimumab Market Tells You About What Comes Next<\/strong><\/h2>\n\n\n\n

The Post-Settlement Commercial Build<\/strong><\/h3>\n\n\n\n

The adalimumab market is the single most important case study for understanding how biosimilar competition reshapes organizational structures and talent demand. AbbVie settled separately with all nine major biosimilar manufacturers, granting early European market entry dates in exchange for delayed U.S. entry until January 2023. [3] When those January 2023 launches finally came, the companies that had been waiting out the litigation needed commercial organizations already in place, not being assembled in real time.<\/p>\n\n\n\n

Amgen’s Amjevita launched first in the U.S. in January 2023. Seven more products launched in July 2023. Within 18 months, biosimilars captured approximately 80% of new adalimumab prescriptions. [13] That kind of market penetration does not happen without substantial commercial infrastructure: payer relations teams negotiating formulary placement, field forces educating physicians, medical affairs teams generating real-world evidence, and patient support services matching the scale of AbbVie’s own.<\/p>\n\n\n\n

The companies that built those commercial organizations during the litigation wait period \u2014 particularly between 2020 and 2022, when settlement dates were clear but launch was still prohibited \u2014 hired aggressively from two talent pools: innovator pharma commercial functions, and the generic pharmaceutical commercial teams that understood formulary negotiations and rebate contracting. That cross-sector recruiting pattern is now visible again in every therapeutic area where a major biologic settlement has recently been reached.<\/p>\n\n\n\n

Sandoz, which acquired the Cimerli (ranibizumab) business from Coherus in January 2024 for $170 million, explicitly purchased not just a product and regulatory filing but also, in its own words, ‘ophthalmology sales and field reimbursement talent.’ [14] That transaction is a direct acknowledgment of what the company needed most: the people who know how to sell in a specialty ophthalmology market. The commercial talent that came with the Cimerli acquisition was not a nice-to-have. It was part of the thesis.<\/p>\n\n\n\n

The Talent Surplus That Followed Humira’s Collapse<\/strong><\/h3>\n\n\n\n

On the other side of that commercial build-out, AbbVie’s U.S. revenue from Humira declined from approximately $17 billion annually to competitive levels within 24 months of biosimilar entry. That decline produced something rare in biopharma: a large pool of experienced commercial talent \u2014 medical science liaisons, market access directors, brand managers, field medical directors \u2014 who had been working on a product that was now fighting for survival against 12 competitors.<\/p>\n\n\n\n

Some of that talent was absorbed into AbbVie’s immunology lifecycle programs (Skyrizi, Rinvoq). A portion moved to competing biosimilar companies that needed people who understood the adalimumab patient population and prescriber dynamics. The rest dispersed across the industry, available to companies scaling their biosimilar commercial functions in other indications.<\/p>\n\n\n\n

The biosimilar talent market in 2024 and early 2025 benefited from this supply. A Stifel biopharma market update from late 2025 noted that ‘the hiring conditions of 2022-2023, when highly qualified candidates were suddenly available due to restructuring, are disappearing’ as the broader talent surplus closes. [15] That window is still open in specific Humira-adjacent roles \u2014 but it is narrowing, and the next wave of commercial build-outs will increasingly compete for the same people in a tighter market.<\/p>\n\n\n\n

\n\n\n\n

Part IV: The Biosimilar Void \u2014 The Talent Demand That Nobody Has Yet Recognized<\/strong><\/h2>\n\n\n\n

118 Biologics, 90% Without a Development Program<\/strong><\/h3>\n\n\n\n

One of the most consequential data points in biosimilar market intelligence right now comes from the IQVIA Institute for Human Data Science, which identified what it calls the ‘biosimilar void’: of the 118 biologics expected to lose patent protection in the U.S. between 2025 and 2034, approximately 90% have no publicly disclosed biosimilar in development. [16]<\/p>\n\n\n\n

That figure needs unpacking, because it sounds more alarming than it actually is in aggregate \u2014 many of those 118 molecules represent small-market biologics that cannot justify the $100-300 million development cost of a biosimilar program. But even adjusting for commercial viability, the void is real, and it represents a structural undersupply of biosimilar development capacity that has direct implications for where talent will be needed.<\/p>\n\n\n\n

The molecules where the void matters most are those with large addressable markets where the development cost-to-revenue ratio is favorable. The Inflation Reduction Act’s drug price negotiation provisions have introduced a complicating factor here: a July 2025 report from Matrix Global Advisors warned that IRA price negotiations on biologics may unintentionally deter biosimilar development by compressing the revenue available to both innovator and biosimilar manufacturers in the same molecule. [17] If payers are already negotiating Keytruda’s price down toward a post-exclusivity floor, the economic case for a biosimilar program weakens.<\/p>\n\n\n\n

That dynamic has not stopped at least seven companies from pursuing pembrolizumab biosimilars. But it suggests that the next cohort of molecules \u2014 those expiring in 2027 to 2030 with less obvious commercial upside \u2014 will generate less competition and therefore less talent demand than Keytruda.<\/p>\n\n\n\n

CMC: The Bottleneck Nobody Hires For Until It Is Too Late<\/strong><\/h3>\n\n\n\n

Chemistry, manufacturing, and controls expertise is the most reliably scarce professional category in biosimilar development, and it is also the function that litigation timelines put under the most pressure.<\/p>\n\n\n\n

A biosimilar’s analytical package \u2014 the battery of physicochemical, biological, and clinical similarity tests that form the basis of a BLA submission \u2014 requires CMC expertise that takes a decade to develop and cannot be hired from generalist pharma. The FDA’s revised draft guidance from June 2024 eliminated the requirement for switching studies as a condition for interchangeability designation, which theoretically shortens biosimilar development timelines from 7-8 years to 6.5-7.5 years, with further compression possible if Phase 3 comparative clinical trials are also eliminated. [18] The guidance also cut projected development costs from $100-300 million to $75-250 million, with further reductions possible under the most streamlined pathway.<\/p>\n\n\n\n

Those cost and time reductions are real, but they transfer the burden upstream: without a Phase 3 trial generating clinical data, the analytical similarity package has to be even more comprehensive. More analytical work requires more analytical scientists. More analytical scientists who understand antibody structure, post-translational modifications, and the specific immunogenicity profile of the reference product are exactly what biosimilar companies are currently competing for.<\/p>\n\n\n\n

Formycon, Sandoz, and Bio-Thera all cancelled or modified their Phase 3 trials for pembrolizumab biosimilars in 2025, opting instead for FDA submissions based on Phase 1 data and enhanced analytical characterization. [19] Each of those program modifications required significant CMC team involvement, and they occurred at a time when Keytruda biosimilar programs at Samsung Bioepis, Celltrion, and Amgen were also advancing. The competition for analytical biologists and protein chemists who understand IgG4 antibody characterization \u2014 the relevant molecular class for pembrolizumab \u2014 has been acute, and is concentrated in a narrow pool of people with the right experience.<\/p>\n\n\n\n

\n\n\n\n

Part V: The Litigation Archetypes \u2014 Five Case Studies in Talent Prediction<\/strong><\/h2>\n\n\n\n

Archetype 1: The Patent Fortress (Humira\/AbbVie)<\/strong><\/h3>\n\n\n\n

AbbVie’s Humira strategy \u2014 132 patents, nine settlements, delayed U.S. market entry until January 2023 \u2014 is the extreme version of what innovator-side IP talent can accomplish. The talent profile that built and maintained that fortress is now partially dispersed.<\/p>\n\n\n\n

The relevant talent movement: AbbVie’s IP prosecution team pivoted to protecting Skyrizi (risankizumab) and Rinvoq (upadacitinib). The outside counsel relationships \u2014 Latham & Watkins and others \u2014 transferred some institutional knowledge into new client engagements. Biosimilar companies that went through the full patent dance with AbbVie, including Amgen (which settled in 2019) and Boehringer Ingelheim (which settled last, in May 2019, securing a July 2023 launch date), developed significant internal expertise in navigating a complex BPCIA process that they subsequently applied to other programs. [20]<\/p>\n\n\n\n

Where this talent is now: Amgen’s biosimilar IP team \u2014 which has navigated Humira, Eylea, and Enbrel litigation simultaneously \u2014 represents among the most experienced biosimilar litigation groups in the industry. Samsung Bioepis, which similarly navigated multiple AbbVie settlement negotiations and subsequently the Regeneron Eylea litigation, has built comparable depth. Both companies are recruiting in 2025 and 2026 from overlapping talent pools, and their senior IP professionals are among the most sought-after in the space.<\/p>\n\n\n\n

Archetype 2: The IP Fortress That Held (Enbrel\/Amgen)<\/strong><\/h3>\n\n\n\n

Sandoz received FDA approval for Erelzi, an etanercept biosimilar, in 2016. As of mid-2026, it has still not launched in the United States. Amgen successfully defended Enbrel’s late-expiring manufacturing process patents through district court, the Federal Circuit, and a Supreme Court certiorari denial in 2021. [21] Sandoz filed a new antitrust lawsuit in 2025 alleging Amgen’s acquisition and enforcement of the Roche patents was anticompetitive \u2014 but that case’s resolution is years away. [21]<\/p>\n\n\n\n

For Sandoz, the Enbrel situation represents a nine-year blocking. The teams that developed Erelzi, navigated the BPCIA process, and pursued the litigation have had to find other programs to work on. Some moved to the Cimerli acquisition. Others moved to the Hyrimoz (adalimumab) program, which launched in the U.S. in 2023 after settling with AbbVie. The scientific and regulatory talent that developed Erelzi is still within Sandoz’s organizational memory, but it is not working on that product.<\/p>\n\n\n\n

The talent implication: when a biosimilar program is blocked by litigation for this long, the people on that program either move internally or leave. Those who stay become experts in the specific IP landscape of that molecule. If and when Sandoz’s antitrust case against Amgen produces a resolution \u2014 whether a settlement or a court order clearing the path \u2014 that talent will be immediately relevant again, but in a market that may have changed substantially.<\/p>\n\n\n\n

Archetype 3: The Negotiated Entry (Stelara\/Johnson & Johnson)<\/strong><\/h3>\n\n\n\n

Ustekinumab biosimilars provide the most recent example of how coordinated settlement negotiations shape a commercial talent wave. Johnson & Johnson settled with multiple manufacturers, delaying U.S. entry until early 2025. [22] Multiple biosimilar makers \u2014 including Amgen (Wezlana), Alvotech\/Teva (Selarsdi), and Celltrion (Steqeyma) \u2014 launched in Q1 2025. [23]<\/p>\n\n\n\n

The talent wave that preceded those launches started in mid-to-late 2023, when settlement dates became clear. Companies with settlement agreements began building their ustekinumab commercial teams, hiring market access leads from AbbVie’s and J&J’s immunology franchises, recruiting gastroenterology and dermatology medical science liaisons, and signing field account managers with established payer relationships.<\/p>\n\n\n\n

J&J’s strategic response to the Stelara cliff \u2014 accelerating investment in Tremfya (guselkumab), which targets IL-23 specifically rather than IL-12\/IL-23 dual targeting \u2014 required its own talent realignment. [24] Commercial personnel who had been selling Stelara transitioned to Tremfya responsibilities, while some left for biosimilar competitors who were specifically recruiting physicians and payers who had Stelara experience.<\/p>\n\n\n\n

The pattern here is clear: settlement produces a talent exodus from the originator’s commercial team, a talent build-up at the biosimilar companies, and a residual pool of specialists who understand the patient population available to both sides.<\/p>\n\n\n\n

Archetype 4: The At-Risk Launch (Eylea\/Amgen and Regeneron)<\/strong><\/h3>\n\n\n\n

Amgen’s decision to launch Pavblu at risk in October 2024 \u2014 after the Federal Circuit denied Regeneron’s injunction request \u2014 is the rare case where a biosimilar company absorbs ongoing litigation risk in exchange for early market entry. [9] That decision required a specific kind of organizational confidence: the company’s IP and regulatory leadership had to believe, based on their reading of the patent landscape and litigation trajectory, that they would ultimately prevail on the merits, or at minimum that the economic value of early market entry outweighed the damages exposure.<\/p>\n\n\n\n

That decision also required a commercial team ready to launch immediately. Amgen built that team during the litigation period, hiring for the ophthalmology specialty channel while simultaneously fighting Regeneron in court. The at-risk launch posture is not something a company improvises. It is the product of months of parallel preparation by commercial, regulatory, legal, and manufacturing teams \u2014 all of whom need to be in place before the court denies the injunction, not after.<\/p>\n\n\n\n

For talent purposes, the at-risk launch archetype identifies companies with unusually high organizational capability in cross-functional biosimilar programs. The professionals who execute at-risk launches \u2014 regulatory affairs leads who can manage post-launch label negotiations, commercial teams who can activate distribution chains within weeks of a court ruling, IP counsel who can maintain parallel litigation tracks while managing a commercial product \u2014 are among the most capable and sought-after people in the biosimilar field.<\/p>\n\n\n\n

Archetype 5: The Next Wave Fortress (Keytruda\/Merck)<\/strong><\/h3>\n\n\n\n

Merck’s strategy for Keytruda, the world’s best-selling oncology drug at $29 billion in 2024 revenue, is a real-time demonstration of how the Humira playbook is being adapted for the oncology context. [24] With 237 patents filed around the original pembrolizumab molecule and a new subcutaneous formulation approved in September 2025 with patent protection estimated through 2039, Merck is constructing barriers that will shape the biosimilar market for a decade. [5, 6]<\/p>\n\n\n\n

The talent movement this creates is, at this moment, primarily on the biosimilar side. Seven major companies are advancing pembrolizumab biosimilar programs: Samsung Bioepis, Sandoz, Celltrion, Bio-Thera, Amgen, Formycon, and others. [7] They are collectively recruiting the same narrow pool of oncology-focused regulatory scientists, oncology commercial leads, and PD-1 pathway experts who understand the Keytruda label’s 40-plus approved indications. Those indications represent the commercial challenge: a Keytruda biosimilar must be prepared to compete across non-small cell lung cancer, melanoma, head and neck squamous cell carcinoma, and a dozen other settings, each with its own physician community, payer dynamics, and market access challenge.<\/p>\n\n\n\n

The analytical teams working on these programs are largely invisible \u2014 working on Phase 1 pharmacokinetics studies, generating the comparative analytical data packages that the FDA’s revised guidance now makes the centerpiece of the BLA, and managing the patent dance exchanges that will define the first round of BPCIA litigation in 2026 and 2027. They are among the busiest people in biopharma right now, and they are extremely reluctant to move.<\/p>\n\n\n\n

\n\n\n\n

Part VI: The Settlement Timeline as a Hiring Calendar<\/strong><\/h2>\n\n\n\n

Reading the Settlement Dates<\/strong><\/h3>\n\n\n\n

A biosimilar company that agrees to a licensed entry date has, in effect, signed a hiring calendar without publishing it. The table below maps major recent and pending biosimilar settlements to their talent implications:<\/p>\n\n\n\n

Eylea (aflibercept) \u2014 settled cluster, 2024-2025<\/strong><\/p>\n\n\n\n

Amgen’s Pavblu launched at-risk in October 2024. Biocon settled in April 2025 for a second-half 2026 U.S. launch. Sandoz settled in September 2025 for Q4 2026. Samsung Bioepis settled for a January 2027 U.S. launch. Alvotech settled for Q4 2026. [9, 10, 11, 12, 25]<\/p>\n\n\n\n

This cluster of five ophthalmology biosimilars creates simultaneous commercial infrastructure needs across five companies, all concentrated in the retinal disease specialty channel. The pool of experienced ophthalmology biosimilar field medical directors, reimbursement specialists for anti-VEGF agents, and patient services managers who understand retinal injection center workflows is not large. Companies recruiting for Eylea biosimilar commercial functions in 2025 and 2026 are competing with each other for a thin talent pool.<\/p>\n\n\n\n

Stelara (ustekinumab) \u2014 launched cluster, Q1 2025<\/strong><\/p>\n\n\n\n

Multiple companies launched ustekinumab biosimilars in Q1 2025 after their settlement dates cleared. [23] The commercial build-outs for these programs peaked in 2023 and 2024, drawing heavily on people with experience in dermatology and gastroenterology specialty channels. Those builds are now complete, and the organizational structures are stabilizing. Companies that over-hired for the ustekinumab wave are already evaluating whether their commercial overhead can be sustained at the margins biosimilar markets deliver.<\/p>\n\n\n\n

Rinvoq (upadacitinib)\/AbbVie \u2014 future litigation signal<\/strong><\/p>\n\n\n\n

Latham & Watkins recently represented AbbVie in securing five patent litigation settlements protecting Rinvoq until 2037. [26] That date \u2014 2037 \u2014 tells a precise story: any biosimilar company that begins a upadacitinib program today is looking at 11 or more years before a licensed U.S. entry. Companies that invest in Rinvoq biosimilar programs now will need talent with unusually long investment horizons, and they will be recruiting scientists and IP professionals willing to commit to a program that does not generate revenue until the mid-2030s.<\/p>\n\n\n\n

Keytruda (pembrolizumab) \u2014 litigation horizon, 2026-2028<\/strong><\/p>\n\n\n\n

With primary U.S. patent expiry in 2028 and BLA submissions potentially as early as 2026 or 2027, the first BPCIA patent dance exchanges for pembrolizumab are underway or imminent. [27] The companies that filed first \u2014 Samsung Bioepis and Sandoz, which modified their Phase 3 trial designs in 2025 \u2014 are the most likely first-filers. When those BPCIA exchanges begin generating patent lists, the talent demand will shift from development scientists to litigation support scientists, IP patent analysts, and regulatory attorneys who understand the specific claim landscape of PD-1 antibody patents.<\/p>\n\n\n\n

\n\n\n\n

Part VII: Three Talent Profiles in Motion Right Now<\/strong><\/h2>\n\n\n\n

Profile 1: The BPCIA Specialist Litigator<\/strong><\/h3>\n\n\n\n

Biosimilar patent litigation under the BPCIA requires a category of attorney that barely existed before 2012. These professionals combine deep knowledge of patent claim construction, FDA regulatory pathways, and the specific scientific principles underlying biologic drugs. They need to understand antibody-drug interactions, protein characterization methods, and clinical pharmacology well enough to cross-examine expert witnesses effectively.<\/p>\n\n\n\n

The demand for these professionals has grown continuously since the first BPCIA cases were filed. Firms like Sterne Kessler, Goodwin Procter, Alston & Bird, and Duane Morris have built dedicated BPCIA practices, with Sterne Kessler ranking as the most active law firm overall in PTAB ANDA litigation as of 2025. [28]<\/p>\n\n\n\n

Within in-house legal teams, the demand follows the same pattern. Companies actively engaged in BPCIA litigation \u2014 Regeneron (plaintiff), Amgen (defendant and plaintiff), Samsung Bioepis, Celltrion, Sandoz, Biocon \u2014 each maintain dedicated IP litigation functions that are now growing as the next wave of compounds enters the litigation cycle. The attorneys who work at those in-house functions and want to move do so either laterally to another biopharma in-house function (usually when their company’s litigation posture is consolidating) or to outside counsel (when they want broader exposure across multiple programs).<\/p>\n\n\n\n

There is also a flow in the other direction: litigators who spent years at firms like Goodwin or Latham building BPCIA expertise are increasingly attractive to in-house functions at biosimilar companies that want their principal litigation counsel one desk away during active patent dance negotiations. Samsung Bioepis’s U.S. expansion, Celltrion’s investment in direct U.S. commercialization, and Alvotech’s growth from Icelandic startup to multi-product commercial-stage company have each created in-house IP leadership positions that were filled in 2024 and 2025 by lawyers moving from outside counsel roles.<\/p>\n\n\n\n

Profile 2: The CMC\/Analytical Biologist<\/strong><\/h3>\n\n\n\n

As described above, CMC expertise is the production bottleneck in biosimilar development. The FDA’s revised interchangeability guidance from June 2024 \u2014 eliminating switching study requirements \u2014 has redirected investment from clinical execution toward analytical characterization. [18] That means the demand for analytical biologists who can run state-of-the-art characterization assays on monoclonal antibodies, fusion proteins, and other large molecules has increased even as overall development timelines have shortened.<\/p>\n\n\n\n

The specific skills in demand: mass spectrometry-based glycan analysis (critical for immunogenicity assessment), surface plasmon resonance for binding affinity characterization, hydrogen-deuterium exchange mass spectrometry for higher-order structure analysis, and potency assay development. These are not skills taught in a one-year training program. The scientists who have them trained at innovator companies \u2014 typically at Amgen, Genentech\/Roche, Pfizer, or AstraZeneca \u2014 and spent years on innovator analytical development teams before considering biosimilar work.<\/p>\n\n\n\n

The movement from innovator to biosimilar side has been gradual but has accelerated since 2022. When innovator companies restructure \u2014 either because a blockbuster has lost exclusivity or because M&A integration has created redundancies \u2014 their analytical development groups are often the first to be consolidated. The 2025 biopharma market saw significant layoffs in large pharma analytical functions, particularly as Roche\/Genentech managed the post-Avastin and post-Herceptin competitive environment. Scientists displaced from those functions are directly relevant to biosimilar analytical programs, and biosimilar companies have been recruiting them actively.<\/p>\n\n\n\n

The salary premium that biosimilar developers are offering reflects the scarcity. Recruiters in the space report that analytical scientists with five or more years of monoclonal antibody characterization experience command base salaries 15-25% above comparable innovator roles, compensating for the perceived career risk of moving to a company whose products are, by definition, copies of someone else’s invention.<\/p>\n\n\n\n

Profile 3: The Oncology Biosimilar Commercial Lead<\/strong><\/h3>\n\n\n\n

The third and most forward-looking talent profile is the commercial professional who understands how to sell biosimilars in oncology. This role did not exist at scale three years ago. It exists now because trastuzumab (Herceptin) biosimilars have been marketed since 2019, rituximab (Rituxan) biosimilars since 2019, and bevacizumab (Avastin) biosimilars since 2020. The people who ran those commercial programs \u2014 who negotiated with hospital oncology pharmacies, built GPO contracts, managed physician concerns about switching, and developed patient communication materials \u2014 represent a first-generation cohort of oncology biosimilar commercial experts.<\/p>\n\n\n\n

Those people are now being recruited by the companies preparing for the pembrolizumab wave. The gap is this: trastuzumab, rituximab, and bevacizumab are relatively straightforward biosimilar commercial propositions \u2014 large-molecule oncology drugs sold primarily through hospital channels where formulary committees make the switching decision. Pembrolizumab is different. It has more than 40 approved indications, is used across outpatient, community, and academic settings, and is prescribed by oncologists who may have strong brand preferences built over years of Keytruda use.<\/p>\n\n\n\n

The commercial professionals who can navigate that complexity \u2014 who understand the difference between lung cancer and melanoma prescriber dynamics, who have experience explaining biosimilar switching to oncologists skeptical about anything other than Merck’s product, who know how to structure value-based contracts with payers in a market where Merck itself is deploying significant resources to defend its position through subcutaneous formulation launches and patient support programs \u2014 are among the most valuable people in the industry right now.<\/p>\n\n\n\n

Samsung Bioepis and Sandoz, both of which are among the most advanced in pembrolizumab biosimilar development, are competing for the same small cohort of oncology biosimilar commercial leaders. So are Celltrion and Amgen. The hiring competition in this function will intensify significantly as 2027 approaches and BLA submissions for pembrolizumab begin clearing the FDA review pipeline.<\/p>\n\n\n\n

\n\n\n\n

Part VIII: Geographic Talent Flows \u2014 The Korea Factor<\/strong><\/h2>\n\n\n\n

Samsung Bioepis and Celltrion’s U.S. Ambitions<\/strong><\/h3>\n\n\n\n

The Korean biosimilar duopoly \u2014 Samsung Bioepis and Celltrion \u2014 has produced some of the most active and consequential organizational buildouts in the global biosimilar industry. Their contrasting strategies create different talent demands.<\/p>\n\n\n\n

Celltrion has pursued vertical integration: internalized R&D, manufacturing, and direct U.S. commercialization, with 250,000 liters of bioreactor capacity in Songdo and a planned acquisition of an Eli Lilly biologics facility in the U.S. for approximately $320 million in late 2025. [29] That strategy embeds manufacturing talent in-house rather than relying on contract manufacturers. It requires process engineers, quality systems managers, and supply chain professionals who can support a direct U.S. commercial model. Celltrion has been recruiting those professionals from legacy biotech manufacturing hubs \u2014 specifically Cambridge\/Boston, San Francisco Bay Area, and Research Triangle Park in North Carolina \u2014 for at least three years.<\/p>\n\n\n\n

Samsung Bioepis has taken the opposite approach: contract manufacturing through Samsung Biologics, with commercial partnerships across Biogen, Organon, Harrow, and Teva for different products. [29] That partnership model keeps Samsung Bioepis’s internal headcount relatively lean but requires different expertise: alliance management, regulatory alignment across partner organizations, and the ability to coordinate commercial execution through multiple U.S. partners who may have different strategic priorities.<\/p>\n\n\n\n

The talent implications diverge accordingly. Celltrion needs internal manufacturing professionals and direct commercial leads. Samsung Bioepis needs sophisticated alliance managers, regulatory affairs professionals experienced in partner coordination, and business development executives who can structure and manage complex co-commercialization agreements.<\/p>\n\n\n\n

Both companies face a challenge that affects all Korean and European biosimilar entrants in the U.S. market: the people with the deepest knowledge of U.S. payer dynamics, U.S. GPO contracting, and U.S. specialty pharmacy networks are concentrated in U.S. companies and U.S. geographies. Recruiting them requires offering equity or cash compensation that competes with the far larger U.S. biopharma companies, plus the organizational autonomy that smaller entrants can offer but that larger established players often cannot. For talented commercial executives in their late 30s and early 40s who want meaningful responsibility without waiting a decade to reach senior level at a large company, the Korean biosimilar companies’ U.S. buildouts have been attractive opportunities \u2014 and continue to be.<\/p>\n\n\n\n

Indian and Icelandic Operators<\/strong><\/h3>\n\n\n\n

Two other biosimilar companies deserve specific mention for the talent dynamics they represent: Biocon Biologics (India) and Alvotech (Iceland).<\/p>\n\n\n\n

Biocon Biologics acquired Viatris’s biosimilar business in 2022, inheriting an existing U.S. commercial team with products on market. After settling the Eylea litigation with Regeneron in April 2025, Biocon is now preparing a second-half 2026 U.S. launch for Yesafili. [11] That launch requires commercial hiring in the ophthalmology specialty channel on a compressed timeline, and Biocon is competing against Sandoz, Samsung Bioepis, Alvotech, and Amgen for the same pool of anti-VEGF commercial talent.<\/p>\n\n\n\n

Alvotech, the Icelandic biosimilar company founded in 2013, secured a $1.2 billion deal with Teva\/Regeneron in early 2025 for Eylea biosimilar co-development and signed its U.S. settlement with Regeneron for a Q4 2026 entry date. [13, 25] Alvotech’s manufacturing is conducted in Reykjavik, and its commercial execution in the U.S. relies on Teva’s field force and market access infrastructure. The talent demand Alvotech generates is therefore concentrated in development, analytical, and regulatory functions at its Iceland headquarters \u2014 creating a specific talent flow from U.S. and European biosimilar development teams to a non-traditional biopharma hub that compensates with equity and the appeal of meaningful scientific challenge.<\/p>\n\n\n\n

\n\n\n\n

Part IX: DrugPatentWatch as a Talent Intelligence Tool<\/strong><\/h2>\n\n\n\n

Professional talent teams at biosimilar and innovator companies use patent databases in ways that are adjacent to but distinct from their intended purpose.<\/p>\n\n\n\n

DrugPatentWatch, which tracks patent expiry dates, secondary patent portfolios, litigation activity, BLA filings, and Freedom to Operate analysis for drugs across the industry, has become an essential resource not just for legal and regulatory teams but for business development, investor relations, and \u2014 increasingly \u2014 human resources and executive recruiting functions. [30] When a biosimilar company’s BD team identifies a target molecule by querying DrugPatentWatch for biologics with near-term primary patent expiries and no publicly announced biosimilar programs, it is generating, simultaneously, a list of molecules for potential development and a list of skills the company will need to hire.<\/p>\n\n\n\n

The molecules with 2027 to 2029 patent expirations and thin biosimilar pipelines \u2014 the ‘biosimilar void’ molecules \u2014 represent the forward-looking talent demand. Companies that identify these molecules now and begin building the development teams to address them will have the skill sets in place when the development-to-filing window opens. Companies that wait will compete in a seller’s market for the same small pool of specialists.<\/p>\n\n\n\n

The PTAB activity data within these databases is equally informative. PTAB biologic and biosimilar activity in 2024 fell compared to 2023, with 11 inter partes review petitions filed and no post-grant reviews, versus 22 IPR petitions and two PGRs in 2023. Eight of those 2024 IPRs targeted Keytruda’s patents. [5] That concentration tells a very specific story: the companies that filed IPRs against Merck’s pembrolizumab patents in 2024 are signaling their seriousness about the program and creating paper trails of their patent positions that sophisticated talent candidates can read. An analytical scientist considering joining a pembrolizumab biosimilar program can \u2014 and should \u2014 read those IPR petitions before accepting an offer. The strength of the company’s patent challenge strategy reflects the quality of its IP team, and the quality of its IP team predicts the difficulty of the scientific work it is asking that scientist to do.<\/p>\n\n\n\n

Medical and pharmaceutical petitions, including those for biologics, remained relatively steady at 12.7% of PTAB activity in 2025, indicating sustained interest despite the uncertainty. [6]<\/p>\n\n\n\n

\n\n\n\n

Part X: The IRA Wild Card and Its Talent Consequences<\/strong><\/h2>\n\n\n\n

Price Negotiations and the Biosimilar Development Calculus<\/strong><\/h3>\n\n\n\n

The Inflation Reduction Act’s drug price negotiation provisions have introduced structural uncertainty into biosimilar economics that did not exist before 2022. The core concern, documented in the Matrix Global Advisors report from July 2025, is that when the federal government negotiates a drug’s price down toward a post-exclusivity floor, it compresses the price gap between the originator and a potential biosimilar. [17] A biosimilar’s commercial value derives primarily from its price discount relative to the branded drug. If the branded drug’s price is already being negotiated down, the biosimilar’s entry has less economic impact \u2014 which means less revenue to justify the $75-250 million development cost.<\/p>\n\n\n\n

This is not a hypothetical concern. Eliquis, which faces generic entry in 2026, was among the first drugs negotiated under the IRA. The experience of the Eliquis small-molecule generics \u2014 facing a pricing floor set by government negotiation rather than raw market competition \u2014 provides an early signal for what biosimilar developers of IRA-negotiated biologics might face.<\/p>\n\n\n\n

For talent purposes, the IRA uncertainty has had two effects. First, it has made the economics of biosimilar programs harder to model with confidence, which slows hiring decisions at companies that need board-level approval for major pipeline investments. Second, it has redirected some biopharma talent toward policy and government affairs functions at biosimilar companies, as those companies recognize that legislative and regulatory outcomes have become as important as scientific execution in determining program success.<\/p>\n\n\n\n

The Samsung Bioepis white paper from July 2025 \u2014 which called for ‘free pricing at launch’ for biosimilars, multi-winner tenders, and minimum price boundaries to prevent excessive price erosion \u2014 reflects the commercial intelligence that these companies are now building into their strategic functions. [17] Companies that hire policy experts and health economics professionals who understand IRA dynamics alongside their development and commercial teams will be better positioned to navigate the next decade’s market than those that treat policy as external noise.<\/p>\n\n\n\n

\n\n\n\n

Part XI: The M&A Signal \u2014 When Acquisitions Flag Talent Gaps<\/strong><\/h2>\n\n\n\n

M&A as a Talent Admission<\/strong><\/h3>\n\n\n\n

When a biosimilar company acquires another company’s product, it is often because it lacks the specific talent to build that capability internally on the required timeline. The Sandoz acquisition of Cimerli from Coherus in January 2024 \u2014 paying $170 million for a product, its regulatory filing, its commercial infrastructure, and, explicitly, its ‘ophthalmology sales and field reimbursement talent’ \u2014 is the clearest recent example. [14]<\/p>\n\n\n\n

Sandoz did not buy Cimerli because it could not develop a ranibizumab biosimilar scientifically. It had the manufacturing capability. It bought Cimerli because it did not have the ophthalmology commercial team that could serve retinal disease specialists, and it was faster and cheaper to acquire one than to build one from scratch. The $170 million included those people.<\/p>\n\n\n\n

That logic \u2014 buy the team, get the asset \u2014 has become increasingly common in biosimilars as the market has matured. Acquiring a commercial-stage biosimilar product provides not just revenue but organizational capability. The people who come with the acquisition know the accounts, know the payers, know the prescribers, and know the competitive dynamics of that specific therapeutic niche. Their institutional knowledge is worth more than the regulatory dossier.<\/p>\n\n\n\n

For executives inside smaller biosimilar companies with commercial products, this acquisition dynamic is relevant. A company with an approved, commercial-stage product in a specialty channel where a large biosimilar operator wants to build scale is not just a pipeline asset. It is a talent acquisition target.<\/p>\n\n\n\n

The M&A Wave and Talent Displacement<\/strong><\/h3>\n\n\n\n

The broader M&A environment in biopharma, which generated more than $30 billion in monthly activity across consecutive months in late 2025, also drives talent displacement. [15] When Novartis acquired Avidity Biosciences for $12 billion, signaling conviction in RNA therapeutics, the integration created immediate redundancies in Avidity’s research, clinical, and operational functions. Those displaced professionals are available to biosimilar companies and innovator companies alike, and they bring specific expertise in RNA biology and oligonucleotide manufacturing that is relevant to next-generation biologic programs.<\/p>\n\n\n\n

The integration effect \u2014 highly skilled professionals displaced from acquired companies and available for three to nine months before the broader market absorbs them \u2014 creates short windows for targeted biosimilar recruiting that most HR functions are too slow to exploit. The companies that move first during those displacement windows, offering meaningful roles to people with specific capabilities they need, gain talent that would otherwise be unavailable.<\/p>\n\n\n\n

\n\n\n\n

Part XII: What the Next 36 Months Look Like<\/strong><\/h2>\n\n\n\n

The Pembrolizumab Cohort<\/strong><\/h3>\n\n\n\n

The talent demand centered on pembrolizumab biosimilar development will peak between mid-2026 and late 2027. That window covers the period when BLA submissions for pembrolizumab biosimilars will begin landing at FDA, BPCIA patent dance exchanges will be underway, and commercial infrastructure decisions will be irreversible. Companies that have not hired their oncology commercial leadership by Q3 2026 will face serious difficulties executing a 2028 or 2029 U.S. launch.<\/p>\n\n\n\n

The specific roles that will be hardest to fill: senior regulatory affairs directors with BPCIA BLA experience in oncology, senior IP litigation counsel with PD-1 patent expertise, and oncology market access directors who have negotiated formulary placements for biosimilars in non-Hodgkin lymphoma, lung cancer, or melanoma settings.<\/p>\n\n\n\n

The Ophthalmology Wave<\/strong><\/h3>\n\n\n\n

The Eylea settlement cluster means that five companies will be building or activating U.S. ophthalmology commercial teams in 2025 and 2026 simultaneously. The ophthalmology specialty pharma talent pool \u2014 retinal specialists, optometrist coverage managers, ophthalmic injection center administrators \u2014 is not large. Companies that began their commercial buildouts in 2024 have a head start on those that are hiring in 2025 or 2026.<\/p>\n\n\n\n

Sandoz, with the Cimerli acquisition already providing an infrastructure foundation, and Amgen, which launched Pavblu at-risk and has been building commercial coverage since October 2024, have structural advantages in this talent competition. Samsung Bioepis, targeting a January 2027 U.S. launch for OPUVIZ, has a slightly longer runway \u2014 but that runway will not feel long in 2026 when it is trying to hire in the same therapeutic channel where Sandoz, Amgen, and Biocon are all also active.<\/p>\n\n\n\n

The 2030 Molecules<\/strong><\/h3>\n\n\n\n

Looking past the current wave, the biologics expiring between 2028 and 2032 represent the talent demand that no one has adequately prepared for. The IQVIA biosimilar void data suggests that many of those molecules will enter their competitive windows without robust biosimilar programs in place. The companies that identify the viable commercial opportunities within that cohort now, begin hiring the CMC talent to develop them, and lay the IP groundwork while the litigation horizon is still years away, will be the organizations that dominate the following decade of the biosimilar market.<\/p>\n\n\n\n

The profile of the professionals who should be leading that preparation: scientists with 10 to 15 years of biologic drug development experience, IP attorneys with five or more years of BPCIA practice, and commercial executives who have run a specialty biosimilar product through its full launch lifecycle at least once. Those professionals exist. They are working at Sandoz, Amgen, Samsung Bioepis, Celltrion, Biocon, and the dozen smaller biosimilar developers that have grown through the 2023-2025 wave. They are not advertising that they are open to new opportunities. But the talent intelligence embedded in patent litigation data, settlement timelines, and IPR activity tells you who the next employers are \u2014 and the smartest ones will reach those professionals before those professionals decide to move on their own.<\/p>\n\n\n\n

\n\n\n\n

Conclusion: The Patent Register Is a Hiring Calendar<\/strong><\/h2>\n\n\n\n

The link between patent litigation and talent migration in biopharma is not a loose correlation. It is a mechanical relationship driven by the economics of biosimilar development and the BPCIA’s litigation timeline requirements.<\/p>\n\n\n\n

When a biosimilar company wins a settlement with a licensed entry date, it has committed \u2014 in public, in a legal document \u2014 to a commercial launch that requires specific human capabilities to execute. Reverse-engineering that commitment against a talent acquisition timeline tells you, with reasonable precision, what that company will be hiring for and when. Patent thickets, IPR challenges, at-risk launches, and negotiated entries are not just legal events. They are organizational inflection points that drive talent demand across the industry.<\/p>\n\n\n\n

The companies that understand this relationship \u2014 and use litigation data as a leading indicator of competitive talent demand \u2014 will recruit the right professionals before the competition identifies the same need. The companies that wait for the need to become obvious will bid against five peers for the same candidate pool.<\/p>\n\n\n\n

The patent clock is running. The hiring clock is the same clock.<\/p>\n\n\n\n

\n\n\n\n

Key Takeaways<\/strong><\/h2>\n\n\n\n

Settlement dates are hiring calendars.<\/strong> When a biosimilar company negotiates a licensed U.S. entry date, it has implicitly committed to a commercial team buildout timeline. Most require full commercial infrastructure 12-18 months before launch, and regulatory and CMC teams years before that.<\/p>\n\n\n\n

CMC talent is the scarcest resource in biosimilar development.<\/strong> The FDA’s revised interchangeability guidance from June 2024 eliminated switching study requirements but increased the analytical burden on CMC teams. Analytical biologists with monoclonal antibody characterization expertise command meaningful salary premiums and are the most competitive hires in the space.<\/p>\n\n\n\n

Keytruda’s 2028 patent expiry is generating talent demand right now.<\/strong> Seven companies are building pembrolizumab biosimilar programs. The oncology commercial leads, regulatory affairs directors with BPCIA BLA experience, and PD-1 patent litigators they will need in 2026-2027 are being identified and recruited today.<\/p>\n\n\n\n

The Eylea settlement cluster is producing a simultaneous ophthalmology commercial buildout.<\/strong> Five companies secured U.S. launch dates in Q4 2026 to January 2027. The ophthalmology specialty commercial talent pool is not large enough to staff all five programs without significant competition.<\/p>\n\n\n\n

PTAB activity and IPR petitions are advance signals of program seriousness.<\/strong> Companies that file inter partes review petitions against a reference product’s patents are declaring their investment in that program months or years before their BLA submission. Eight of the 11 biopharma IPR petitions in 2024 targeted Keytruda patents \u2014 a clear signal of where development investment is concentrated.<\/p>\n\n\n\n

The biosimilar void beyond 2027 represents the next talent opportunity.<\/strong> With 90% of biologics losing exclusivity between 2025 and 2034 lacking publicly disclosed biosimilar programs, the organizations that begin hiring now for molecules expiring in the early 2030s will face far less competition for both market position and talent.<\/p>\n\n\n\n

M&A in biosimilars is increasingly a talent acquisition mechanism.<\/strong> Sandoz’s purchase of Cimerli from Coherus explicitly acquired the ophthalmology commercial team alongside the product. Companies with commercial-stage biosimilar products in specialty channels are talent acquisition targets, not just pipeline assets.<\/p>\n\n\n\n

\n\n\n\n

FAQ<\/strong><\/h2>\n\n\n\n

Q1: How precisely can a biosimilar company’s hiring timeline be predicted from its patent litigation activity?<\/strong><\/p>\n\n\n\n

The prediction is most reliable for commercial function hiring after a settlement agreement is signed. The settlement date provides a hard anchor: a company with a Q4 2026 licensed entry date needs its commercial infrastructure broadly in place by Q2 2026 and its regulatory affairs lead in place no later than Q3 2025. CMC and analytical hiring timelines are harder to read from litigation alone, but IPR petition filings \u2014 which signal the company’s seriousness about the development program \u2014 typically precede CMC hiring peaks by 18 to 24 months. Databases like DrugPatentWatch, which track both patent disputes and BLA pipeline activity, provide the underlying data to build this timeline in real time.<\/p>\n\n\n\n

Q2: What does the FDA’s June 2024 interchangeability guidance change about who biosimilar companies hire?<\/strong><\/p>\n\n\n\n

The guidance eliminated switching study requirements for interchangeability designation, which previously required dedicated clinical trial design and patient safety monitoring teams. By shifting the evidentiary burden from clinical trial execution to comparative analytical characterization, the guidance effectively increased demand for analytical scientists and reduced demand for clinical operations professionals within biosimilar programs. Companies that previously built large clinical operations functions for interchangeability studies are now redirecting those resources or reducing those headcounts, while analytical development teams are expanding. The net effect is a talent reallocation from one development function to another, concentrated in 2024 and 2025.<\/p>\n\n\n\n

Q3: Are the talent flows from innovator companies to biosimilar companies a one-way street?<\/strong><\/p>\n\n\n\n

No, and the counterflow is worth tracking. Professionals who develop expertise at biosimilar companies \u2014 particularly in BPCIA patent litigation, analytical development for complex biologics, and biosimilar commercial execution \u2014 are increasingly attractive to innovator companies that need people who understand the competitive threat from biosimilar entry. AbbVie, J&J, Merck, and Regeneron all hire former biosimilar executives into lifecycle management, patent strategy, and competitive intelligence roles. The expertise that makes someone good at challenging a patent thicket is also useful in designing one. The most strategically experienced professionals in this space have worked on both sides of the BPCIA, and they command a premium accordingly.<\/p>\n\n\n\n

Q4: How does the Korean biosimilar industry’s growth affect the global talent pool?<\/strong><\/p>\n\n\n\n

Samsung Bioepis and Celltrion have both built significant U.S.-based commercial and regulatory functions that draw talent from the same pools as U.S. biosimilar companies. Their presence has expanded the number of employers competing for experienced U.S. biopharma talent, particularly in regulatory affairs, market access, and specialty commercial roles. South Korea’s domestic market has faced a ‘brain drain’ challenge \u2014 talented scientists pursuing better compensation and facilities in the U.S. and China \u2014 which has led to government incentive programs for talent retention and inbound recruitment. The two dynamics create a circular talent flow: Korean companies hiring U.S.-based commercial talent while losing domestic scientific talent to U.S. and Chinese employers, which then feeds back into the U.S. pool.<\/p>\n\n\n\n

Q5: What is the single most underestimated talent need in biosimilar programs today?<\/strong><\/p>\n\n\n\n

Health economics and outcomes research (HEOR) professionals who can build the evidence package needed for biosimilar formulary acceptance are chronically undervalued until a company is six months from launch and does not have anyone who can answer a pharmacy and therapeutics committee’s question about real-world outcomes. Biosimilar substitution decisions at large health systems are not made on price alone. They require comparative evidence on clinical outcomes in switched patients, confidence in safety profiles, and support for physician education. The HEOR function \u2014 building that evidence, publishing it, and making it available to payers \u2014 is consistently under-resourced in biosimilar commercial buildouts and consistently identified, retrospectively, as a gap. The companies that hire HEOR leads early, rather than treating it as a pre-launch afterthought, will have a structural advantage in formulary negotiations.<\/p>\n\n\n\n

\n\n\n\n

References<\/strong><\/h2>\n\n\n\n

[1] Association for Accessible Medicines. (2025, July 8). Patent thickets and litigation abuses hinder all biosimilars<\/em>. AAM. https:\/\/accessiblemeds.org\/resources\/press-releases\/patent-thickets-and-litigation-abuses-hinder-all-biosimilars\/<\/p>\n\n\n\n

[2] Petrie-Flom Center, Harvard Law School. (2021, January 6). AbbVie wins first round in Humira antitrust lawsuit<\/em>. https:\/\/petrieflom.law.harvard.edu\/2021\/01\/06\/abbvie-humira-antitrust-patent-thicket\/<\/p>\n\n\n\n

[3] Mintz. (2020, June 18). AbbVie’s enforcement of its ‘patent thicket’ for Humira under the BPCIA<\/em>. https:\/\/www.mintz.com\/insights-center\/viewpoints\/2231\/2020-06-18-abbvies-enforcement-its-patent-thicket-humira-under<\/p>\n\n\n\n

[4] Bloomberg Law \/ Haug Partners. (2022). AbbVie’s Humira patent portfolio not an antitrust violation<\/em>. https:\/\/haugpartners.com\/article\/abbvies-humira-patent-portfolio-not-an-antitrust-violation\/<\/p>\n\n\n\n

[5] Pharmacy Times. (2026, February 20). Soaring off the patent cliff: Preparing for the next wave of oncology biosimilars<\/em>. https:\/\/www.pharmacytimes.com\/view\/soaring-off-the-patent-cliff-preparing-for-the-next-wave-of-oncology-biosimilars<\/p>\n\n\n\n

[6] Biosimilars Law Bulletin \/ Rothwell Figg. (2025, July 16). Biosimilars boom: 2025’s fast track approvals look to reshape healthcare<\/em>. https:\/\/www.biosimilarsip.com\/2025\/07\/16\/biosimilars-boom-2025s-fast-track-approvals-look-to-reshape-healthcare\/<\/p>\n\n\n\n

[7] Biosimilars IP. (2025). Biosimilars Law Bulletin: Pembrolizumab biosimilar developments<\/em>. https:\/\/www.biosimilarsip.com<\/p>\n\n\n\n

[8] Fish & Richardson. (2025, February 24). Biologics and biosimilars landscape 2024: IP, policy, and market developments<\/em>. https:\/\/www.fr.com\/insights\/thought-leadership\/blogs\/biologics-and-biosimilars-landscape-2024-ip-policy-and-market-developments\/<\/p>\n\n\n\n

[9] Grand View Research. (2025). Aflibercept (Eylea) market: Strategic shifts post-patent expiry and biosimilar impact<\/em>. https:\/\/www.grandviewresearch.com\/market-trends\/aflibercept-market-strategic-shifts-post-patent-expiry-biosimilar-impact<\/p>\n\n\n\n

[10] Pearce IP. (2025, September 9). Sandoz’s biosimilar aflibercept US launch set for Q4 2026 following Regeneron settlement<\/em>. https:\/\/www.pearceip.law\/2025\/09\/09\/sandozs-biosimilar-aflibercept-us-launch-set-for-q4-2026-following-regeneron-settlement\/<\/p>\n\n\n\n

[11] Eyes on Eyecare. (2025, April 16). Settlement paves way for US commercialization of Eylea biosimilar<\/em>. https:\/\/glance.eyesoneyecare.com\/stories\/2025-04-16\/settlement-paves-way-for-us-commercialization-of-eylea-biosimilar\/<\/p>\n\n\n\n

[12] Ophthalmology Times. (2026). Samsung Bioepis reaches settlement agreement for Eylea (aflibercept) biosimilar<\/em>. https:\/\/www.ophthalmologytimes.com\/view\/samsung-bioepis-reaches-settlement-agreement-for-eylea-aflibercept-biosimilar<\/p>\n\n\n\n

[13] chinapathology.org. (2025, December 28). Future biosimilars: Upcoming patent expirations and market entry<\/em>. https:\/\/chinapathology.org\/future-biosimilars-upcoming-patent-expirations-and-market-entry<\/p>\n\n\n\n

[14] GaBI Online. (2024). Sandoz US acquisition of ranibizumab biosimilar from Coherus<\/em>. https:\/\/gabionline.net\/pharma-news\/sandoz-us-acquisition-of-ranibizumab-biosimilar-from-coherus<\/p>\n\n\n\n

[15] GeneCoda. (2025, December 5). Biopharma market update 2025: Impacts on talent, hiring, and growth<\/em>. https:\/\/www.genecoda.com\/blog\/biopharma-market-update-2025-impacts-on-talent-hiring-and-growth\/<\/p>\n\n\n\n

[16] DrugPatentWatch. (2025, December 4). The biosimilar launch window: A predictive framework for navigating patents, payers, and litigation<\/em>. https:\/\/www.drugpatentwatch.com\/blog\/the-biosimilar-launch-window-a-predictive-framework-for-navigating-patents-payers-and-litigation\/<\/p>\n\n\n\n

[17] Center for Biosimilars. (2025, July 31). Biosimilars news roundup: July 2025<\/em>. https:\/\/www.centerforbiosimilars.com\/view\/biosimilars-news-roundup-july-2025<\/p>\n\n\n\n

[18] Biosimilars Law Bulletin. (2025). FDA interchangeability guidance: Switching study elimination and its development implications<\/em>. https:\/\/www.biosimilarsip.com\/<\/p>\n\n\n\n

[19] Biosimilars Law Bulletin. (2025, July 16). Phase 3 trial cancellations for pembrolizumab biosimilars: Formycon, Sandoz, Bio-Thera<\/em>. https:\/\/www.biosimilarsip.com\/2025\/07\/16\/biosimilars-boom-2025s-fast-track-approvals-look-to-reshape-healthcare\/<\/p>\n\n\n\n

[20] BioPharma Dive. (2019, May 14). With Boehringer settlement, AbbVie completes Humira sweep<\/em>. https:\/\/www.biopharmadive.com\/news\/abbvie-boehringer-ingelheim-settle-humira-patent-biosimilar\/554729\/<\/p>\n\n\n\n

[21] DrugPatentWatch. (2025, November 20). A strategic guide to biologic patent exclusivity and competitive advantage<\/em>. https:\/\/www.drugpatentwatch.com\/blog\/a-strategic-guide-to-biologic-patent-exclusivity-and-competitive-advantage\/<\/p>\n\n\n\n

[22] Center for Biosimilars. (2024, November 11). Breaking down biosimilar barriers: The patent system<\/em>. https:\/\/www.centerforbiosimilars.com\/view\/breaking-down-biosimilar-barriers-the-patent-system<\/p>\n\n\n\n

[23] Biosimilars Law Bulletin. (2025, July 16). 2025 off to a fast start: 12 biosimilar approvals<\/em>. https:\/\/www.biosimilarsip.com\/2025\/07\/16\/biosimilars-boom-2025s-fast-track-approvals-look-to-reshape-healthcare\/<\/p>\n\n\n\n

[24] DrugPatentWatch. (2026, March 10). The patent cliff playbook: Pharmaceutical IP valuation, generic entry timing, and biosimilar strategy<\/em>. https:\/\/www.drugpatentwatch.com\/blog\/patent-expirations-seizing-opportunities-in-the-generic-drug-market\/<\/p>\n\n\n\n

[25] SEC\/Alvotech. (2025). Alvotech Form 6-K: AVT06 Regeneron settlement agreement<\/em>. https:\/\/www.sec.gov\/Archives\/edgar\/data\/0001898416\/000117184325008028\/exh_991.htm<\/p>\n\n\n\n

[26] Latham & Watkins. (2025). Life sciences IP litigation: AbbVie Rinvoq settlements<\/em>. https:\/\/www.lw.com\/en\/practices\/intellectual-property-litigation\/life-sciences-ip-litigation<\/p>\n\n\n\n

[27] Grand View Research. (2025). Pembrolizumab (Keytruda) market: Navigating the patent cliff and strategic implications<\/em>. https:\/\/www.grandviewresearch.com\/market-trends\/pembrolizumab-market-navigating-patent-cliff-strategic-implications<\/p>\n\n\n\n

[28] Sterne Kessler. (2025). Pharmaceutical patent litigation<\/em>. https:\/\/www.sternekessler.com\/services\/litigation\/pharmaceutical-litigation\/<\/p>\n\n\n\n

[29] Korea Biomedical Review. (2025, December 29). Celltrion and Bioepis split on sales and manufacturing as biosimilar margins compress<\/em>. https:\/\/www.koreabiomed.com\/news\/articleView.html?idxno=30126<\/p>\n\n\n\n

[30] DrugPatentWatch. (2024, October 11). Predicting patent litigation outcomes for biosimilars<\/em>. https:\/\/www.drugpatentwatch.com\/blog\/predicting-patent-litigation-outcomes-for-biosimilars\/<\/p>\n","protected":false},"excerpt":{"rendered":"

How litigation patterns, settlement timelines, and competitive pressure in biologics are rewriting the industry’s talent map \u2014 and what that […]<\/p>\n","protected":false},"author":1,"featured_media":38510,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-38507","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/38507","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=38507"}],"version-history":[{"count":1,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/38507\/revisions"}],"predecessor-version":[{"id":38511,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/38507\/revisions\/38511"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/38510"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=38507"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=38507"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=38507"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}